Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: Safety, pharmacokinetics and activity

Investigational New Drugs

Volumn 33, Issue 3, 2015, Pages 611-620

  Awada, Ahmad ^a   Dumez, Herlinde ^b   Aftimos, Philippe G ^a   Costermans, Jo ^b   Bartholomeus, Sylvie ^a   Forceville, Kathleen ^b   Berghmans, Thierry ^a   Meeus, Marie Anne ^c   Cescutti, Jessica ^d   Munzert, Gerd ^e   Pilz, Korinna ^e   Liu, Dan ^e   Schöffski, Patrick ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Boehringer Ingelheim   (Belgium)

^d BOEHRINGER INGELHEIM   (France)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Phase I trial; Platinum therapy; Polo like kinase inhibitor; Solid tumors; Volasertib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CELL CYCLE PROTEIN; CISPLATIN; ONCOPROTEIN; PLATINUM; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; VOLASERTIB;

ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL CYCLE PROTEINS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PLATINUM; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; YOUNG ADULT;

EID: 84939943880     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0223-9     Document Type: Article

References (25)

1. Schöffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14:559-570
2. Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643-660
3. Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100:5789-5794
4. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94:1863-1877
5. Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX (2011) Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. Cancer Biother Radiopharm 26:427-436
6. Cheng MW, Wang BC, Weng ZQ, Zhu XW (2012) Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochem 114:503-509
7. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K (1997) Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14:543-549
8. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94:148-152
9. Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB, Pan X, Yin YM (2012) Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int J Biochem Cell Biol 44:200-210
10. Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 18:BR237-BR246
11. Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321-330
12. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094-3102
13. Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48:179-186
14. Baum A, Gurtler U, Munzert G, Steegmaier M (2006) In vivo efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase PIK1, in combination with various cytotoxic agents. Eur J Cancer Suppl 4:110-111
15. Kreis NN, Sommer K, Sanhaji M, Kramer A, Matthess Y, Kaufmann M, Strebhardt K, Yuan J (2009) Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle 8:460-472
16. Baum A, Garin-Chesa P, Gurtler U, Munzert G, Rudolph DI (2007) Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinoma. J Thorac Oncol(Supplement 2):S435, abstr
17. Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K (2006) Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 66:5836-5846
18. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
19. US Food and Drug Administration (2013) Recommendations on Carboplatin Dosing. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm228974.htm. Accessed 24 September 2014
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
21. Accord Healthcare Limited (2012) Carboplatin 10 mg/ml concentrate for solution for infusion. Summary of Product Characteristics
22. Accord Healthcare Limited (2012) Cisplatin 1 mg/ml concentrate for solution for infusion. Summary of Product Characteristics
23. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161-183
24. van der Vijgh WJ (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242-261
25. Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels JP (2013) A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol 24:1392-1400